Scantox Neuro GmbH

Founded

1999

Staff

100

Organization type

RDM biotech/pharma

Region

Styria

Scantox Neuro was formerly QPS Neuropharmacology. We are specialists in Neuropharmacology and offer preclinical studies in CNS diseases, Rare Diseases and Mental Disorders. The on-site availability of highly predictive disease models, unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes Scantox Neuro the first choice for most CNS drug development needs.

R&D:Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease (NPC1), Gaucher Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Frontotemporal Lobar Degeneration (FTLD) and other neurodegenerative and rare diseases.